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Abstract
Background: Adipocyte fatty acid-binding protein, also known as aP2 or fatty acid-binding protein 4 (FABP4),
plays an important role in inflammatory and metabolic responses in adipocytes and macrophages. Recent
work has demonstrated that macrophage FABP4 integrates inflammatory and lipid metabolic responses, thereby
contributing to the development of insulin resistance and atherosclerosis. However, it is not known whether FABP4 in
human pulmonary artery endothelial cells(HPAECs) modulates inflammation.
Results: Here, we demonstrate that FABP4 and inflammatory cytokines are upregulated in lipopolysaccharide(LPS)-
stimulated HPAECs. In addition, LPS increases the expression of molecules in the arachidonic acid(AA)–cyclooxygenase
(COX) 2 signaling pathway in FABP4-expressing, but not FABP4-deficient, HPAECs.
Conclusions: Our findings demonstrate that silencing FABP4 could decrease inflammatory cytokines, which
were reported to be expressed via the AA–COX2 pathway, in HPAECs. In addition, silencing FABP4 could
inhibit the expression of molecules in the AA–COX2 pathways. So we speculate silencing FABP4 could decrease the
inflammatory response in HPAECs, which involves in the AA–COX2 signaling pathway. Our study suggests that FABP4
could be a potential biomarker and intervention point for the inflammation-related disease in HPAECs such as
pulmonary thromboembolism.
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Background
Vascular endothelial cells inhibit platelet adhesion and
anticoagulation in normal conditions, which is mainly
dependent on the integrity of endothelial cells. Vascular
endothelial injury is the most important and common
cause of thrombosis [1]. And the inflammation, which
might be the primary process or response to injury of
endothelial cell, could lead to initiate thrombus formation
[2]. Accompanied by pulmonary artery endothelial injury
and inflammatory reaction, pulmonary thromboembo-
lism(PTE) would initiate and develop [3, 4]. PTE is a com-
mon illness, which caused by the obstruction of thrombus
in pulmonary artery and its branches, with high mortality
and morbidity [5]. The most common diagnostic tests for
PTE are the D-dimer blood test, which has poor specifi-
city, and computed tomography, which has low sensitivity
at the early stage of PTE [6]. Thus, there is an urgent
need to identify accurate biomarkers to facilitate the
early diagnosis of PTE.
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Our previous studies showed that the expression of
FABP4 is increased in an animal model of PTE [7].
FABP4 is a key enzyme in the regulation of intracellular
lipid metabolism and, in turn, lipid metabolism is linked
to inflammatory response [8]. Since the occurrence of
PTE is accompanied by injury to vascular endothelial
cells and inflammation, we postulated that FABP4 may
involve in PTE-associated inflammatory activity.
FABP4 belongs to a family of small molecular weight
(15 kDa) cytoplasmic fatty acid-binding proteins that
bind with high affinity to unsaturated long-chain fatty
acids [9]. FABP4 is expressed in a highly tissue-specific
manner. In adipocytes, FABP4 plays a role in regulating
lipid metabolism and insulin sensitivity. In macrophages,
FABP4 regulates cholesterol ester accumulation and in-
flammatory activity [10]. A recent study has demon-
strated that suppression of FABP4 protects mice against
atherosclerosis and compromises the inflammatory re-
sponses of macrophages [11]. Another study showed
that FABP4-deficient mice are resistant to several other
inflammatory disorders [12]. These findings suggest that
FABP4 modulates the inflammatory response in adipo-
cytes and macrophages. However, the role of FABP4 in
HPAECs has not yet been studied.
To address the question, we investigated the events
underling LPS-stimulated FABP4 expression in HPAECs.
Our study showed that PTE increases serum concentra-
tions of the inflammatory mediators tumor necrosis
factor-α (TNF-α), interleukin (IL)-1β, and IL-6. Since
these mediators are induced downstream of AA metab-
olism by COX2 [13, 14], this finding suggested that the
AA–COX2 pathway participates in PTE-associated in-
flammatory activity. AA is an unsaturated long-chain
fatty acid that can be metabolized to diverse products
depending on the expression and activity of various en-
zymes. In the normal physiological state, AA is stored in
the cell membrane in the form of phospholipids, and re-
leased from the cell membrane when cells are activated
by stimuli [15]. There were no reported of the relation-
ship between FABP4 and the metabolism of AA, except
a reported of AA could induce the expression of FABP4
in adipocyte [16]. So, the objective of the present study
was to investigate the relationship between FABP4 and
the AA metabolic cascade in inflammatory responses.
Methods
Human serum measurements
All subjects (20 PTE patients from Affiliated Hospital of
Nantong University and 20 healthy volunteers) were
fasted overnight for 12 h. The next day at 7:00, we ex-
tracted elbow vein blood placed in EDTA-anticoagulant
tube, and then centrifuged it at 4 °C to separate serum.
Cytokines were measured in serum by a commercially
available ELISA kit (R&D System, USA). The study was
approved by the Ethics Committee of Hospital Affiliated
to Nantong University (2105-036).
Cell culture
Human pulmonary artery endothelial cell (American
Type Culture Collection, Manassas, VA, USA) were cul-
tured in DMEM medium(HyClone, Logan City, Utah,
USA) supplemented with 2 mM L-glutamine, 100 U/Ml
penicillin, 100 mg/mL streptomycin and 10% fetal bo-
vine serum (Gibco BRL, Grand Island, NY, USA).
Cells were grown in a 5% CO2 humidified atmosphere
at 37 °C.
Cellular inflammation modeling
Cells were incubated in DMEM medium containing free
bovine serum albumin overnight. They were then rinsed
with serum-free DMEM medium and exposed to LPS
from E.coli (SO55:B5; Sigma-Aldrich) or vehicle. We se-
lected the most effective concentration and time by
western blot and RT-PCR analysis.
ShRNA transfection
Three small hairpin RNA targeting human FABP4 mRNA
(named shRNA) and negative control duplex (named NC)
were chemically synthesized by Biomics Biotech, Nantong,
China. The sequences of shFABP4 and negative control






UGUGGAAAGGUUCCCTT-3’. Negative control shRNA
sequences were (scramble) sense,5’-UUCUCCGAACGU
GUCACGUTT-3’ and antisense,5’-ACGUGACACGUUC
GGAGAATT-3’. Cells were then transfected by Lipofecta-
mine 2000 reagents (Invitrogen, USA) according to
the manufacturer’s instructions. We selected the one
most effective silencing sequence by western blot and
RT-PCR analysis.
Cell viability
Cells were seeded on 96-well plates at a cell density of
1 × 105 cells/mL. Cell viability was measured at different
hours(0, 24, 48, 72 and 96 h) after transfected at shRNA
concentration of 50 nM. 10ul CCK8 (Dojindo Laborator-
ies, Japan) solution was added to the well. After incu-
bated at 37 °C for 1 h, the cell absorbance (A) at 450 nm
was measured at the MRX II absorbance reader (Dynex
Technologies, USA). [Experimental group cell viability
= (experimental group A value—cell free group A value)/
(control group A value—cell free group A value) ×
100%]. The experiment was repeated three times with 3
wells per group
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PCR (qRT-PCR)
Total RNA was extracted from cells using Trizol reagent
(Invitrogen, Carlsbad, CA, USA), and reverse transcribed
to cDNA using a Revert AidTM First Strand cDNA syn-
thesis kit (Fermentas, Glen Burnie, MD, USA) following
the supplier’s instructions. The primers (Table 1) used
for real-time RT-PCR purchased from Biomics Biotech
(Nantong, China). The transcripts were quantified with
SyberGreen on an ABI 7500 thermal cycler (Applied
Biosystems). The levels of expressed genes were quan-
tified with the 2-ΔΔCt method after normalizing to an
endogenous reference GAPDH. The experiment was
performed in triplicate.
Western blot
The total proteins extract from HPAECs and were ob-
tained using a lysis buffer (Beyotime Institute of Biotech-
nology, Nantong, China). Proteins were separated by
SDS-polyacrylamidegel electrophoresis in 15% gels, and
transferred to Polyvinylidene Fluoride(PVDF) Membrane
(Millipore Corporation, USA) at 300 mA for 40 min.
The membrane was blocked with 5% fat-free milk in
PBS and 0.5% Tween-20 (TBST) for 1 h at room tem-
perature(RT) and then incubated with the following pri-
mary antibodies overnight at 4 °C: monoclonal rabbit
anti-FABP4 (1:500 dilution; Abcam, UK), monoclonal
rabbit anti-COX2 (1:1000 dilution; Abcam, UK). After
washing three times with TBST, horseradish peroxidase-
conjugated (HRP)-conjugated goatanti-rabbit antibody
(1:3000, biosharp, USA) was incubated with membrane
for 1 h at RT. After stripping, the membrane was
reprobed with β-actin(1:1000, Abcam, UK) overnight at
4 °C, followed by incubation with secondary antibody as
above at room temperature for 2 h. Protein detection
was performed using the enhanced chemiluminescence
(ECL) system (Millipore, Bedford, MA).
ELISA
Supernatants from cells (FABP4-deficient HPAECs or nor-
mal cells) were evaluated for secreted inflammatory cyto-
kines, including TNF-α, IL-6 and IL-1β, by ELISA (R&D
System, USA) after 0 or 1 μg/ml LPS treatment for 24 h.
These cytokines were measured according to the manufac-
turer’s instructions. For analysis of PGE2 secretion, cells
were also stimulated with LPS, and assayed via ELISA.
LC-MS/MS determination of arachidonic acid
Arachidonic acid was quantitatively spiked into cell solu-
tion, and then takes the supernatants after super-speed
centrifuged. Samples were separated on a Phenomenex
Luna C18 column with a mobile phase, which consisted
of water-0.02% formic acid (solvent A) and acetonitrile-
0.02% formic acid (solvent B). A gradient separation was
programmed at a flow rate of 200 μL/min-1 and
temperature of the column was 35 °C. The electrospray
ionization (ESI) mass spectrometer and negative and
positive ionization modes mode to detect arachidonic
acid (m/z 303.2) by liquid chromatography-tandem mass
spectrometry (LC-MS/MS, AB SCIEX, Comcord, ON).
An ion spray voltage was set to -5.5/4.5 kV (negative/
positive) with electrospray ion source (turbo spray)
temperature at 400 °C. All instrumentations were syn-
chronized with Analyst Software (versions 1.5.1) of ABI.
Statistical analysis
Data in the paper are expressed as means ± standard de-
viations (SDs) or means ± standard errors of means
(SEMs). Statistical significance was determined by a one-
way analysis of variance or Student’s t test.
Results
FABP4 expression is associated with the inflammatory
response and is increased in HPAECs by LPS treatment
We found that levels of TNF-α, IL-1β, and IL-6 are signifi-
cantly higher in the serum of patients with PTE compared
with healthy subjects (n = 20) (Fig. 1a), as measured by
ELISA, and these inflammatory cytokines were reported to
be expressed via the AA–COX2 pathway [13, 14]. Com-
pared with normal people, patients with PTE showed
greatly increased secretion of IL-1β (28.95 ± 2.70 vs 18.01 ±
2.83 ng/L; t = 12.49, P < 0.001), IL-6 (13.11 ± 3.39 vs 5.79 ±
1.53 ng/L; t = 8.78, P < 0.001), and TNF-α (476.80 ± 30.05
vs 197.80 ± 53.73 ng/L; t = 20.27, P < 0.001). Using genomic
and metabolomic approaches, we also found that FABP4 is
upregulated in animal models of PTE. Thus, we speculate
that the inflammatory response observed in PTE patients
may be mediated by the AA signaling cascade. We first ex-
amined the expression of FABP4 in HPAECs. Western blot
analysis showed that treatment of HPAECs with LPS sig-
nificantly increased expression of FABP4 protein in a con-
centration- and time-dependent manner (Fig. 1b and c).
Table 1 Primer sequences for real-time PCRs
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Gray value analysis showed the protein level of FABP4
was highest in cells stimulated with 1 μg/ml(F = 111.12,
P < 0.001) of LPS for 24 h(F = 70.29, P < 0.001). Consist-
ent with the changes in FABP4 protein levels, FABP4
mRNA levels were elevated approximately 3-, 15- and
4-fold following stimulation with LPS at 0.1, 1, and
10 μg/ml LPS, respectively, for 24 h. Thus, the expres-
sion of FABP4 mRNA was highest in cells stimulated
with 1 μg/ml LPS(F = 177.80, P < 0.001) (Fig. 1d).
FABP4 expression is silenced in HPAECs transfected with
FABP4-specific shRNA
We next tested three shRNA sequences for their ability to
silence FABP4 expression in HPAECs by performing west-
ern blot and qPCR analysis of FABP4 protein and mRNA
levels, respectively. Cells were transfected with one of
three shFABP4 (shRNA-1, shRNA-2, and shRNA-3) or a
negative control shRNA. We found that shRNA-3 was the
most effective sequence for silencing FABP4 expression in
both protein level(F = 57.79, P < 0.001) and mRNA level(F
= 34.85, P < 0.001) (Fig. 2a and b), and this was therefore
used in the following loss-of-function experiments. Then
we examined the effect of shRNA transfection on cell via-
bility at 0, 24, 48, 72 and 96 h (Fig. 2c). CCK8 assay
showed there was no significant difference (F = 2.92, P =
0.077) in cell viability at all times. Thus, the damage of
shRNA transfection to the cells could be negligible.
LPS-induced expression of the inflammatory cytokines
(TNF-α, IL-1β, and IL-6) is reduced in shFABP4 HPAECs
FABP4 participates in the inflammatory response evoked
by various stimuli [17]. In the HPAECs (the untransfected
Fig. 1 FABP4 expression is associated with the inflammation and is increased in HPAECs by LPS treatment. a The expression of TNF-α, IL-1β, IL-6
in the patients with pulmonary embolism and normal people were analyzed by ELISA. Results are shown as mean ± SD, n = 20, ***P < 0.001
compared to normal people. Western bolt was used to detect the protein level of FABP4 in cells stimulated with b) 0 μg/ml, 0.1 μg/ml, 1 μg/
ml, 10 μg/ml of LPS and c) 1 μg/ml of LPS for 0 h, 2 h, 4 h, 8 h, 12 h, 24 h, 48 h. β-actin was used as loading control to quantitative analysis
of the relative density. Data are presented as mean ± SD, n = 3, ***P < 0.001. d qRT-PCR was used to detect FABP4 mRNA expression in cells stimulated
with four different concentrations of LPS normalized to GAPDH. Data are presented as means ± SEM, n = 3, ***P < 0.001
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and unstimulated cell), expression of the inflammatory cy-
tokines (TNF-α, IL-1β, and IL-6) was increased in response
to LPS stimulation, as detected by ELISA or qRT-PCR
(Fig. 3a and b). To determine whether inhibition of
FABP4 modulates the development of this inflamma-
tory response, we transfected cells with shFABP4 and
analyzed inflammatory cytokine mRNA levels in LPS-
stimulated cells by qRT-PCR. This analysis showed that
in LPS-stimulated group the cells transfected with
shFABP4 expressed lower levels of TNF-α, IL-1β, and
IL-6 mRNA(respective t = 6.62, P = 0.022; t = 6.82, P =
0.020 and t = 5.56, P = 0.031) compared with normal
cells (Fig. 3a). We also examined cytokine protein se-
cretion by ELISA. Compared with normal cells, shFABP4-
transfected cells showed greatly reduced secretion of IL-
1β (14.98 ± 0.39 vs 24.38 ± 0.83 ng/L; t = 17.71, P < 0.001),
IL-6 (4.27 ± 0.13 vs 7.78 ± 0.18 ng/L; t = 26.82, P < 0.001),
and TNF-α (207.39 ± 7.43 vs 427.63 ± 5.69 ng/L; t = 40.76,
P < 0.001) in response to LPS stimulation (Fig. 3b). Thus,
FABP4 deficiency attenuates the LPS-induced inflamma-
tory response of HPAECs.
FABP4 plays an important role in AA signaling cascade
We next investigated whether FABP4 is involved in AA
signaling. Prostaglandin E2(PGE2), a product of AA
metabolism by COX, is an important mediator of the
inflammatory response. Stimulated with LPS, shFABP4-
transfected cells showed greatly lower expression of
COX2 in protein level(t = 27.85, P < 0.001) and mRNA
level(t = 34.37, P < 0.001) than normal cells(Fig. 4a).
Similar results were obtained when PGE2 levels were
examined(Fig. 4b). Whereas there was no significant dif-
ference in PGE2 expression between unstimulated con-
trol(t = 1.97, P = 0.120) and FABP4-silenced cells(t = 1.86,
P = 0.136), PGE2 expression in LPS-treated shFABP4-
transfected cells was significantly lower than in stimu-
lated control cells(t = 11.29, P < 0.001). We also analyzed
AA levels in HPAECs by liquid chromatography-tandem
mass spectrometry (LC-MS/MS) (Fig. 4c–e). As shown
in Fig. 4e, the concentration of AA was significantly
lower in LPS-stimulated shFABP4-transfected cells than
in LPS-stimulated normal cells (21.09 ± 5.88 vs 91.39 ±
4.38 ng/mL; t = 17.81, P < 0.001). Collectively, these data
suggest that silencing of FABP4 gene expression by RNA
interference inhibited the AA–COX2 cascade.
Discussion
Our previous work using genomic and proteomic ap-
proaches showed that FABP4 expression was upregu-
lated in an animal model of PTE. In addition, FABP3 has
been reported to be a promising indicator for PTE [18]
and similar to FABP4 in structure [19], which suggests
Fig. 2 Three different sequences of shRNA for silencing FABP4 transfect into HPAECs. a Western blot was used to detect the protein level of FABP4 in
normal cells and cells transfected by three different sequences of shRNA and negative control duplex(named NC). β-actin was used as
loading control to quantitative analysis of the relative density. Data are presented as means ± SD, n = 3, ***P < 0.001. b qRT-PCR was used
to detect the most effective sequence. Data are presented as means ± SEM, n= 3, ***P< 0.001. c CCK8 was used to detect the cell viability. Data are
presented as means ± SEM, n= 3
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FABP4 could be closely related to PTE. Then, we also
found that inflammatory cytokines, such as TNF-α, IL-
1β, and IL-6, were more abundant in patients with PTE
than in healthy subjects. Therefore, we hypothesized that
FABP4 may be involved in the inflammatory response in
PTE. Although several studies have demonstrated the
importance of FABP4 for macrophage inflammatory re-
sponses, the specific contributions of FABP4 to inflam-
mation in HPAECs has not been fully explored.
Here, we found that downregulation of FABP4 mRNA
and protein levels reduced the inflammatory cytokines
in HPAECs. We further investigated the link between
FABP4 and inflammation in HPAECs. LPS treatment of
inflammatory cells is known to stimulate the release of
inflammatory cytokines [20, 21]. We found that silencing
of FABP4 decreased inflammatory cytokine production
in LPS-stimulated endothelial cells, which is consistent
with previous reports of a relationship between FABP4
and inflammatory cytokine production in inflammatory
cells [22–24]. While the mechanism by which this oc-
curs had remained elusive, our research sheds light on
this by showing FABP4-mediated modulation of the in-
flammatory response in HPAECs.
Our study provides the first evidence that FABP4 potenti-
ates LPS-induced inflammatory response in HPAECs.
Recent studies have shown that FABP4 modulates
macrophage inflammatory responses through a positive
feedback loop involving c-Jun kinase and activator
protein-1 [25]. FABP4 contributes to lipid metabolism
[26], and AA, a major long chain polyunsaturated fatty
acid, has been reported to regulate fat metabolism [27, 28].
We showed here that LPS stimulates the expression
of FABP4 in HPAECs. Interestingly, our finding that
FABP4 deficiency reduced LPS-induced inflammatory
cytokines, which are the downstream molecule of AA
pathway, suggests that FABP4 may modulate the AA
pathway during inflammation.
In this study, we found that FABP4 inhibition sup-
presses the LPS-induced AA pathway and downstream
generation of inflammatory cytokines, such as TNF-α,
IL-1β, and IL-6, in HPAECs. This result implies that
FABP4 inhibitors could be used to prevent the develop-
ment of inflammation-induced diseases.
Another finding in this study is that shRNA-mediated
knockdown of FABP4 attenuates LPS-induced activation
of the AA–COX2 cascade in HPAECs, suggesting that
FABP4 is required for activation of AA signaling. Recent
studies have shown that LPS stimulation induces AA re-
lease from the cell membrane [29, 30]. We showed here
that FABP4 silencing significantly decreased AA release
from membranes in the inflammatory status. Silencing
of FABP4 prevented expression of COX2, which cata-
lyzes the metabolism of AA to PGE2, a major lipid me-
diator involved in various inflammatory diseases [31].
Our results demonstrate that FABP4 expression was sig-
nificantly associated with expression of an enzyme and
Fig. 3 LPS-induced expression of inflammatory cytokines (TNF-α, IL-1β, IL-6) is weakened in shFABP4 HPAECs. TNF-α, IL-1β, IL-6 were produced
from shFABP4-transfected cells and normal cells stimulating by LPS. a qRT-PCR and b ELISA were used to examine the expression levels of TNF-α,
IL-1β, IL-6. Data are presented as means ± SEM, n = 3, *P < 0.05, ***P < 0.001
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metabolite of the AA pathway in HPAECs. However, the
mechanism by which FABP4 activates the AA pathway is
currently unknown.
This study shows that the potentiating effect of
FABP4 on AA activation is dependent on its fatty
acid-binding capacity. FABP4 is a peripheral protein
with a high affinity binding site that non-covalently
binds to fatty acids, increasing their solubility and
transporting them from the lipid membrane to their
sites of action [32–34]. AA and its metabolites may
thus play a role as the primary or secondary signal in
the signal transduction pathway [35]. We speculate
that FABP4 is a ligand for AA [19] and plays a role
in both signal transduction and in transport of fatty
acids. In addition, FABP4 can bind to eicosanoids
such as PGE2 and is involved in their metabolism
and function [36]. Whether or not FABP4 potentiates
activation of the AA signaling pathway through trans-
port and transduce warrants further investigation.
Our findings further support the notion that FABP4
lies at the crossroads of lipid metabolism and inflam-
mation and also raise the possibility that activation of
long chain fatty acids such as AA may also depend
on FABP4 in HPAECs.
Conclusions
We show here that FABP4 RNA interference inhibited
the inflammatory response in HPAECs, and that FABP4
and AA metabolism are involved in perpetuating the in-
flammatory response. Furthermore, disruption of FABP4
activity attenuated the AA cascade and downregulated
production of inflammatory cytokines. Taken together,
our findings that FABP4 inhibition suppresses the in-
flammatory response in vitro and that inflammation is
associated with thrombus formation [37–39] suggest
that FABP4 plays a key role in PTE-associated inflamma-
tion and be associated with resistance to conventional
diagnosis on inflammation-associated diseases.
Fig. 4 The expression of molecules related to AA signaling cascade were down-regulated in shFABP4 HPAECs. a The protein and mRNA level of COX2
were detected by western bolt and qRT-PCR. n = 3, ***P < 0.001. b ELISA was used to examine the expression levels of PGE2. Data are
presented as means ± SEM, n = 3, ***P < 0.001. c Relative intensity of AA by means of LC and MS/MS. d Standard curve line of analytical
standards of AA. e The levels of AA were detected in silencing FABP4 HPAECs and normal cells stimulating by LPS. Data are presented as
means ± SD, n = 3, ***P < 0.001
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